Enterprise Value
162.1M
Cash
373.4M
Avg Qtr Burn
-4.49M
Short % of Float
35.26%
Insider Ownership
38.12%
Institutional Own.
61.95%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IGM-7354 Details Solid tumor/s, Cancer, Hematologic malignancies | Phase 1 Data readout | |
IGM-8444 (DR5) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
IGM-2644 (CD38 x CD3) Details Multiple myeloma | Phase 1 Initiation | |
Imvotamab (IGM-2323) (CD20 x CD3) Details Non-Hodgkin lymphoma, Cancer, Chronic lymphocytic leukemia | Failed Discontinued | |
IGM-6268 Details Solid tumor/s, Cancer | Failed Discontinued |